上海荣正企业咨询服务（集团）股份有限公司 证券简称：科美诊断 证券代码：688468 关于 科美诊断技术股份有限公司 2021 年限制性股票激励计划 作废部分限制性股票 相关事项 之 独立财务顾问报告 2025 年 4 月 | （二）咨询方式 9 | | --- | 一、释义 1、上市公司、公司、科美诊断：科美诊断技术股份有限公司。 2、股权激励计划、限制性股票激励计划、本激励计划：《科美诊断技术股份有 限公司 2021 年限制性股票激励计划（草案）》。 3、限制性股票、第二类限制性股票：符合激励计划授予条件的激励对象在满足 相应的获益条件后分次获得并登记的公司 A 股普通股股票。 4、股本总额：公司股东大会审议通过本计划时公司已发行的股本总额。 5、激励对象：按照本激励计划规定，有资格获得限制性股票的公司（含子公司） 员工。 6、授予日：公司向激励对象授予限制性股票的日期。 7、授予价格：公司授予激励对象每一股限制性股票的价格。 8、有效期：从限制性股票授予之日起到激励对象获授的限制性股票全部归属或 作废失效的期间。 9、归属：激励对象满足获益条件后，上市公司将股票登记至激励对象账户的行 为。 10、归属条 ...

上海市通力律师事务所 关于科美诊断技术股份有限公司 2021 年限制性股票激励计划作废部分已授予尚未归属的限制性 股票相关事项之法律意见书 致:科美诊断技术股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受科美诊断技术股份有限公司(以下简称"公 司")委托,指派朱晓明律师、黄雅程律师(以下合称"本所律师")作为公司特聘专项法律顾 问,就公司 2021 年限制性股票激励计划(以下简称"本次激励计划")作废部分已授予尚未 归属的限制性股票(以下简称"本次作废")相关事项,根据《中华人民共和国公司法》(以下 简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股权激 励管理办法》(以下简称"《管理办法》")、《上海证券交易所科创板股票上市规则》(以下简 称"《上市规则》")和《科创板上市公司自律监管指南第4号 -- 股权激励信息披露》(以下 简称"《股权激励信息披露自律监管指南》")等法律、行政法规和其他规范性文件(以下简称 "法律、法规和规范性文件")和《科美诊断技术股份有限公司章程》的有关规定,就公司本 次作废事项出具本法律意见书。 为出具本法律意见书,本所律师已 ...

Financial Performance - The company's operating revenue for 2024 was CNY 436,289,767.28, a decrease of 2.03% compared to CNY 445,340,815.75 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 127,074,717.39, down 13.77% from CNY 147,373,517.73 in 2023[22]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 100,730,232.14, a decrease of 16.97% compared to CNY 121,317,262.48 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY 167,950,046.11, down 2.95% from CNY 173,053,196.46 in 2023[22]. - The total assets at the end of 2024 were CNY 1,832,158,296.89, an increase of 0.64% from CNY 1,820,562,566.47 at the end of 2023[22]. - The net assets attributable to shareholders at the end of 2024 were CNY 1,416,307,137.37, an increase of 1.98% from CNY 1,388,801,768.59 at the end of 2023[22]. - The basic earnings per share for 2024 were CNY 0.32, a decrease of 13.51% from CNY 0.37 in 2023[23]. - The diluted earnings per share for 2024 were CNY 0.32, reflecting the same decrease of 13.51% compared to CNY 0.37 in 2023[23]. Dividend Distribution - The proposed cash dividend distribution is 1.25 RMB per 10 shares, totaling approximately 49.32 million RMB, which represents 38.82% of the net profit attributable to shareholders for 2024[5]. - The company is currently not planning to increase capital reserves or issue bonus shares[5]. Research and Development - The R&D investment as a percentage of operating revenue for 2024 was 17.71%, down 1.07 percentage points from 18.78% in 2023[23]. - The company has established a strong foundation for its second growth curve by increasing R&D investment and developing new technologies[34]. - The company has developed advanced marker detection technologies for infectious diseases, including next-generation HIV antigen/antibody detection technology and HCV antigen/antibody combined detection technology[60]. - The company has a research and development team of 172 people, accounting for 27.34% of total employees, with R&D investment representing 17.71% of revenue[81]. - The company has significantly increased its R&D investment, establishing a high-quality research team and advanced facilities to support innovation efforts[199]. Market Strategy - The company is focusing on "import substitution" as a long-term strategy, emphasizing innovation and high-quality development in the medical industry[33]. - The company is actively pursuing import substitution in the high-end medical device market, particularly in the field of chemiluminescence immunodiagnostics, which has significant market opportunities[131]. - The company aims to enhance its diagnostic capabilities for diseases such as diabetes and inflammation through innovative technology and product development[67]. Governance and Compliance - The company adheres to strict governance practices, ensuring compliance with laws and regulations while protecting shareholder rights[137]. - The board of directors held 5 meetings in 2024 to discuss key issues, ensuring effective governance and decision-making[138]. - The company has implemented robust information disclosure practices to ensure transparency and protect investor interests[138]. - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring clear responsibilities and effective operations[188]. Innovation and Patents - A total of 64 new patents were granted during the reporting period, including 33 domestic invention patents, showcasing the company's growing innovation capability[36]. - The company has obtained 316 authorized patents, including 131 invention patents, as of December 31, 2024[80]. - The company has developed the LiCA® series clinical diagnostic products, which are competitive with international brands like Roche and Abbott[198]. Operational Efficiency - The company has implemented a salary and welfare budget management system to optimize personnel structure and improve efficiency[165]. - The company has established a comprehensive internal control system that is effectively implemented, ensuring no significant omissions in its operations[185]. - The company has established a multi-level training platform to enhance both organizational and individual employee capabilities[166]. Risks and Challenges - The company faces risks related to new product development, which typically takes 3-5 years from project initiation to registration[86]. - The company faces risks related to intensified market competition, particularly from multinational companies and domestic competitors[91]. - There is a risk of declining gross profit margins due to national centralized procurement policies and rising operational costs[93]. Financial Management - The company plans to apply for a comprehensive bank credit line for 2024, as approved in the annual general meeting[141]. - The company will use idle raised funds for cash management as part of its financial strategy[155]. - The company reported a significant increase in revenue, achieving a total of 31.42% share control through indirect holdings by its chairman, Li Lin[147].

Financial Performance - The company's operating revenue for Q1 2025 was ¥81,300,127.46, a decrease of 27.01% compared to ¥111,390,688.04 in the same period last year[4] - Net profit attributable to shareholders was ¥14,542,813.84, down 62.12% from ¥38,392,507.40 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥11,131,421.96, reflecting a decline of 68.00% compared to ¥34,787,360.92 in the previous year[4] - Basic and diluted earnings per share were both ¥0.04, a decrease of 60.00% from ¥0.10 in the same period last year[4] - Total operating revenue for Q1 2025 was ¥81,300,127.46, a decrease of 27% compared to ¥111,390,688.04 in Q1 2024[18] - Net profit for Q1 2025 was ¥14,542,813.84, a decline of 62% from ¥38,392,507.40 in Q1 2024[19] - Earnings per share for Q1 2025 was ¥0.04, compared to ¥0.10 in Q1 2024, indicating a 60% decrease[19] - Cash received from sales of goods and services in Q1 2025 was ¥90,331,179.04, down 30% from ¥129,981,796.53 in Q1 2024[21] Cash Flow and Assets - The net cash flow from operating activities decreased by 59.74%, amounting to ¥15,204,001.57, down from ¥37,767,684.23[4] - Total assets at the end of the reporting period were ¥1,815,591,513.49, a decrease of 0.90% from ¥1,832,158,296.89 at the end of the previous year[5] - As of March 31, 2025, the company's total current assets amounted to RMB 1,049,855,808.49, a decrease from RMB 1,067,681,904.23 as of December 31, 2024, reflecting a decline of approximately 1.14%[13] - The company's cash and cash equivalents stood at RMB 401,225,526.99, slightly increasing from RMB 400,252,111.81 in the previous period[13] - Total cash inflow from investment activities was $464,799,073.09, down from $503,609,819.16, resulting in a net cash outflow of $51,537,903.44 compared to a net inflow of $60,935,030.35 previously[22] - The ending balance of cash and cash equivalents was $106,768,979.00, significantly lower than $277,035,240.30 at the end of the previous period[23] Liabilities and Equity - Total liabilities decreased to ¥384,741,562.28 from ¥415,851,159.52, representing a reduction of approximately 7.5%[15] - Non-current liabilities totaled ¥237,393,000.93, a slight increase from ¥232,502,428.90[15] - The company reported a decrease in accounts payable from ¥66,627,322.85 to ¥36,201,224.37, a reduction of about 46%[15] - Shareholders' equity attributable to shareholders was ¥1,430,849,951.21, an increase of 1.03% from ¥1,416,307,137.37 at the end of the previous year[5] Research and Development - Research and development expenses totaled ¥17,156,877.91, a decrease of 14.62% from ¥20,095,592.77 year-on-year[4] - The proportion of R&D expenses to operating revenue increased to 21.10%, up 3.06 percentage points from 18.04%[5] - The company is focusing on R&D investments to enhance technology and product innovation, aiming to meet unmet clinical needs and drive import substitution[12] - The company has established a dual-driven strategy focusing on import substitution and clinical interactive innovation to enhance its product pipeline[12] - The company has a robust product pipeline prepared in advance to navigate industry challenges and aims to create a "new quality productivity" for long-term growth[12] Non-Recurring Gains and Other Income - The company reported non-recurring gains totaling ¥3,411,391.88, primarily due to various non-operating income sources[7] Shareholder Information - The top ten shareholders include Ningbo Baoshui District Yingweili Enterprise Management Partnership with 108,000,008 shares, representing a significant stake in the company[11]

4月28日，科美诊断今日收盘6.93元，下跌1.56%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到21.89倍，总市值27.80亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.40倍，行业中值34.81倍，科美诊断排 名第51位。 截至2025年一季报，共有9家机构持仓科美诊断，其中其他9家，合计持股数20628.76万股，持股市值 15.37亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)51科美诊断21.8921.871.9427.80亿行业平均 46.4044.004.49100.23亿行业中值34.8134.782.2645.22亿1硕世生物-1850.69-1850.691.1437.05亿2天益医 疗-1581.08-2708.221.6920.15亿3澳华内镜-525.57263.604.2155.39亿4诺唯赞-508.22-508.222.3391.96亿5康 泰医学-256. ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, which has a current stock price of 6.85 yuan and a rolling PE ratio of 21.64 times, significantly lower than the industry average of 45.94 times [1][2] - Kemei Diagnostics has a total market capitalization of 2.748 billion yuan and ranks 50th in the medical device industry based on PE ratio [1][2] - As of the third quarter of 2024, Kemei Diagnostics reported a revenue of 344 million yuan, a year-on-year decrease of 0.43%, and a net profit of 112 million yuan, down 6.73% year-on-year, with a gross profit margin of 76.35% [1] Group 2 - The company specializes in the research, development, production, and sales of clinical immunochemical luminescent diagnostic reagents and instruments, being one of the earliest high-tech enterprises in China to focus on this field [1] - Kemei Diagnostics has received several honors, including being recognized as a 2022 Beijing Intellectual Property Demonstration Unit and a 2022 municipal enterprise technology center [1] - A total of 62 institutions hold shares in Kemei Diagnostics, with a combined holding of 2.325 million shares valued at 16 million yuan [1]

科美诊断2月28日大宗交易平台出现一笔成交，成交量60.00万股，成交金额459.60万元，大宗交易成交 价为7.66元，相对今日收盘价折价1.16%。该笔交易的买方营业部为机构专用，卖方营业部为中信证券 股份有限公司北京紫竹院路证券营业部。 两融数据显示，该股最新融资余额为1.78亿元，近5日增加3421.30万元，增幅为23.86%。（数据宝） 进一步统计，近3个月内该股累计发生17笔大宗交易，合计成交金额为6518.95万元。 2月28日科美诊断大宗交易一览 证券时报•数据宝统计显示，科美诊断今日收盘价为7.75元，下跌3.61%，日换手率为2.46%，成交额为 7778.51万元，全天主力资金净流出544.66万元，近5日该股累计下跌7.96%，近5日资金合计净流出 4187.62万元。 ...

Financial Performance - Total revenue for 2024 was RMB 43,628.98 million, a decrease of 2.03% compared to the previous year[5] - Operating profit for 2024 was RMB 13,475.09 million, down 18.96% year-over-year[5] - Net profit attributable to shareholders was RMB 12,699.28 million, reflecting a decline of 13.83% from the prior year[5] - Basic earnings per share decreased to RMB 0.32, a drop of 13.51% compared to the previous year[5] - The weighted average return on equity decreased to 9.17%, down 1.56 percentage points from the previous year[3] Assets and Operations - Total assets at the end of the reporting period were RMB 183,216.71 million, an increase of 0.64% from the beginning of the year[5] - The company launched the fully automated immunoassay system LICA® AT 5000, which gained recognition from high-end hospital clients[6] - The company’s R&D and production base in Suzhou has commenced operations, enhancing long-term growth potential[6] Strategic Focus - The company is focusing on precision medicine for diseases such as thyroid, reproductive assistance, cardiovascular, and central nervous system disorders[6] - The company is committed to a "dual-drive" strategy leveraging its leading LICA® technology platform for strong import substitution[6]

科美诊断2月17日大宗交易平台出现一笔成交，成交量50.00万股，成交金额411.50万元，大宗交易成交 价为8.23元，相对当日收盘价折价1.56%。该笔交易的买方营业部为中信证券股份有限公司总部(非营业 场所)，卖方营业部为中信证券股份有限公司北京紫竹院路证券营业部。（数据宝） 超级复盘、主力资金 大宗交易、大宗成交、折溢价、折价、溢价 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 主力资金 2月17日科美诊断大宗交易一览 ...

证券代码：688468 证券简称：科美诊断 公告编号：2024-068 科美诊断技术股份有限公司关于持股 5%以上股东 减持计划完成暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，科美诊断技术股份有限公司（以下简称"公司"）股东 上海沛禧投资管理合伙企业（有限合伙）（以下简称"上海沛禧"）及其一致行动 人 HJ CAPITAL 2 LIMITED（以下简称"HJ CAPITAL"）分别持有公司股份 17,708,910 股、11,273,384 股（合计持有 28,982,294 股），分别占公司总股本 4.41%、 2.81%（合计占公司总股本的 7.23%）。 上述股份来源均为公司首次公开发行股票并上市前持有的股份，且已于 2022 年 4 月 11 日解除限售并上市流通。 减持计划的实施结果情况 公司于 2024 年 10 月 14 日披露了《科美诊断技术股份有限公司关于持股 5% 以上股东减持股份计划公告》（公告编号：2024-0 ...